Last reviewed · How we verify
NCT06799078: RITA-PC
Racial Disparities in Antidepressant Treatment After a Psychiatric Consultation
trial testing Observation while participants receive treatment by their primary care provider in Depression - Major Depressive Disorder in 60 participants. Participants enrolled and being followed up; not accepting new ones.
31 August 2025
Quick facts
| Lead sponsor | Centre for Addiction and Mental Health |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 4 March 2024 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Observation while participants receive treatment by their primary care provider
Conditions studied
- Depression - Major Depressive Disorder — all drugs for Depression - Major Depressive Disorder →
- Depression Disorders — all drugs for Depression Disorders →
Sponsor
Centre for Addiction and Mental Health — full company profile →
Who can join
18 and older, any sex, with Depression - Major Depressive Disorder or Depression Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients from black, indigenous, and people of color (BIPOC) communities are reported to have lower rates of antidepressant adherence and response. The investigators have a limited understanding of why this disparity exists. The majority of outpatient psychiatric consultations are one-time assessments that provide treatment recommendations to the primary care provider. It is important to identify whether there are racial differences in accessing and adhering to recommended treatment plans to provide more equitable care. To the investigators' knowledge, there are no studies that examined racial differences in access and barriers to receiving antidepressant treatment after a one-time psychiatric assessment. This study focuses on patients who were diagnosed with major depressive disorder during a psychiatric consultation 3 months prior. We are examining whether there are racial differences in being a) recommended an antidepressant, b) started/switched to a recommended antidepressant, c) treated at a therapeutic dosage, d) adherence to treatment, and e) whether sociodemographic factors, discrimination in medical settings, and patient perception of depression and antidepressant treatment moderate these differences. This study will inform the development of treatment strategies that minimize racial disparities in the treatment of depression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06799078
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depression - Major Depressive Disorder
Currently open trials in the same condition.
- NCT07372586 — Behavioral Health Collaborative Care Model in an ICU Recovery Clinic · NA · recruiting
- NCT07390786 — Behavioral Health Collaborative Care Model in Post-ICU Clinic Family Pilot · NA · recruiting
- NCT07383467 — No Time to Wait: Single Session Intervention · NA · recruiting
- NCT07026461 — Right-sided 1-Hz Repetitive Transcranial Magnetic Stimulation (rTMS) Versus Left-sided Intermittent Theta Burst Stimulat · Phase 4 · recruiting
- NCT06793397 — A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder · Phase 3 · recruiting
Other Centre for Addiction and Mental Health trials
Trials by the same sponsor.
- NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
- NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
- NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
- NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
- NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06799078 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06799078.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing